GSK shingles vaccine receives FDA approval for adults 50 and over
by Press Release from Outbreak News Today on (#329FV)
GlaxoSmithKline announced Wednesday that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over. FDA Advisory Committees provide non-binding recommendations for consideration by the ["]
The post GSK shingles vaccine receives FDA approval for adults 50 and over appeared first on Outbreak News Today.